OMEROS CORPORATION (NASDAQ:OMER) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders.
The 2018 Annual Meeting of Omeros Corporation, or Omeros, was held on June15, 2018. Shareholders of record at the close of business on April12, 2018 were entitled to vote up to 48,286,842 shares of common stock at the annual meeting. A total of 41,107,604 shares (85.13%) were represented at the annual meeting in person or by proxy. Set forth below is a brief description of each matter voted upon at the annual meeting and the final voting results for each matter.
| (1) | The election of the following two ClassIII directors, each to serve until the 2021 Annual Meeting of Shareholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: |
|
For |
Withheld |
BrokerNon-Votes |
|
|
GregoryA.Demopulos, M.D. |
17,780,436 | 349,868 | 22,977,300 |
|
Leroy E. Hood, M.D., Ph.D. |
16,802,912 | 1,327,392 | 22,977,300 |
| (2) | The ratification of the appointment of Ernst& Young LLP as Omeros’ independent registered public accounting firm for the fiscal year ending December31, 2018. |
|
For |
Against |
Abstain |
BrokerNon-Votes |
| 40,648,141 | 168,148 | 291,315 |
About OMEROS CORPORATION (NASDAQ:OMER)
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement. Its clinical programs include Mannan-binding lectin-associated serine protease-2 (MASP-2) (OMS721)-Lectin Pathway Disorders; PDE10 (OMS824)-CNS Disorders; peroxisome proliferator-activated receptor gamma (PPARy) (OMS405)-Addiction, and OMS201-Urology. Its preclinical programs include phosphodiesterase 7 (PDE7) (OMS527), Plasmin (OMS616), MASP-3 (OMS906)-Alternative Pathway Disorders, GPR17-CNS Disorders, GPR101-Metabolic Disorders, GPR151-CNS Disorders, GPR161-Cancer, GPR174-Immune Disorders, GPR183-Skeletal and Infectious Diseases, GPCR Platform and Antibody Platform.
